Examiner | Jotup

Paltalk, Inc. Reports Increased Operating Efficiencies with 69% Reduction in Net Loss for Fiscal Year 2023

Retrieved on:

Friday, March 15, 2024

Patent, District court, ManyCam, Cisco Webex, Adjustment, Cisco, Examiner, Marketing, Court, Metric, Cryptocurrency

JERICHO, NY, March 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Paltalk, Inc. (“Paltalk,” the “Company,” “we,” “our” or “us”) (Nasdaq: PALT), a communications software innovator that powers multimedia social applications, today announced financial and operational results for the fourth quarter and year ended December 31, 2023.

Key Points:

Jason Katz, Chairman and CEO of Paltalk, commented, “Several of our initiatives have led to a significant decrease in operating expenses and an improvement in reducing our operating and net losses.
On June 29, 2023, the Court held a pretrial conference with the parties and denied Cisco’s motion for summary judgement.
The decrease in net loss was due to the reduction of operating expenses; and
Adjusted EBITDA1 loss for the three months ended December 31, 2023 improved by 52.8% to $0.2 million, compared to Adjusted EBITDA1 loss of $0.5 million for the three months ended December 31, 2022.
Financial Results for Year Ended December 31, 2023
Revenue for the year ended December 31, 2023 and 2022 remained relatively unchanged at $11.0 million.

Infrasense Scans Interstate Bridge Deck Approach Slabs using 3D Ground Penetrating Radar (3DGPR) to Identify Areas of Voiding

Retrieved on:

Tuesday, January 16, 2024

Data analysis, GPS, Software, WATSON, Examiner, Anomaly, CADD, Road

WATSON, Ind., Jan. 16, 2024 /PRNewswire-PRWeb/ -- Infrasense, a pioneering leader in non-destructive infrastructure evaluation, announces the successful completion of a comprehensive void analysis project for four select bridges on a tollway in Indiana.

Key Points:

Infrasense uses cutting-edge 3D Ground Penetrating Radar (3DGPR) technology to identify voids under approach slabs across bridges along a tollway in Indiana.
The project's primary objective was the precise identification of voids in the approach slabs of the bridges.
The software facilitated the stitching of collected data files and enabled comprehensive analysis of approach slabs.
Quantitative Voiding Assessment: The analysis resulted in the identification of voiding activity across the slabs, with detailed quantities provided to the client.

USPTO Issues Final Rejection of Magnolia Medical’s ‘483 Patent at Issue in Litigation

Retrieved on:

Wednesday, December 6, 2023

Professional Services, Health, Legal, General Health, Pharmaceutical, Biotechnology, Kurin, Examiner, Patient, Infection, United States patent law, Patent, Confusion

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the US Patent and Trademark Office has issued a Final Rejection in its reexamination of claims 1 and 24 of U.S. Patent No.

Key Points:

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the US Patent and Trademark Office has issued a Final Rejection in its reexamination of claims 1 and 24 of U.S. Patent No.
10,039,483 (the ‘483 patent).
Claims 1 and 24 of the ‘483 patent were asserted by Magnolia Medical against Kurin’s Lock product in a patent infringement case in Delaware Federal Court.
The USPTO Examiner has rejected Magnolia’s arguments regarding patentability, and the pertinent claims of that patent now stand as rejected.

Fusion Orthopedics Wins Against Extremity Medical on Patent IPR Institution

Retrieved on:

Wednesday, November 29, 2023

View the full release here: https://www.businesswire.com/news/home/20231128329665/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20231128329665/en/
Extremity Medical, LLC (“Extremity Medical”) allegedly filed the ‘166 patent in 2021 targeting the IntraLock, which launched in 2019, for the sole purpose of attempting to harass and extract an unreasonable settlement from Fusion Orthopedics, LLC (“Fusion Orthopedics”).
In Federal Court, Extremity Medical has aggressively sought to enforce invalid patent claims within the ‘166 Patent Family against Fusion Orthopedics, Zimmer Biomet, and Paragon 28.
Fusion Orthopedics believes Extremity Medical has numerous invalid patents that they may assert against Fusion Orthopedics (E.g., U.S. Patent Nos.
This IPR is likely the first of many to be filed against Extremity Medical’s ‘166 Patent Family by Fusion Orthopedics.

High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement

Retrieved on:

Friday, November 10, 2023

United States bankruptcy court, Examiner, Part, Scheme, Latham & Watkins, High court, Plan, Guggenheim Partners, Bankruptcy, AlixPartners, Security (finance), Mallinckrodt

DUBLIN, Nov. 10, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ) (in examination under Part 10 of the Companies Act 2014 of Ireland, and hereinafter "Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that the High Court of Ireland (the "Irish High Court") has made an Order confirming a scheme of arrangement between the Company, its creditors and shareholders (the "Scheme") as proposed by the Examiner of the Company.

Key Points:

DUBLIN, Nov. 10, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ) (in examination under Part 10 of the Companies Act 2014 of Ireland, and hereinafter "Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that the High Court of Ireland (the "Irish High Court") has made an Order confirming a scheme of arrangement between the Company, its creditors and shareholders (the "Scheme") as proposed by the Examiner of the Company.
The Irish High Court also made an Order that the Scheme will become effective on the same date that the Plan becomes effective.
The confirmation of the Scheme by the Irish High Court (and its subsequent effectiveness) satisfies a key condition to the consummation of the Plan.
Confirmation of the Scheme also enables the Company to implement certain important aspects of the Plan in accordance with the laws of Ireland.

Paltalk, Inc. Reports an Increase in Revenue of 5.5% in Third Quarter 2023

Retrieved on:

Tuesday, November 7, 2023

JERICHO, NY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Paltalk, Inc. (“Paltalk,” the “Company,” “we,” “our” or “us”) (Nasdaq: PALT), a communications software innovator that powers multimedia social applications, today announced financial and operational results for the third quarter ended September 30, 2023.

Key Points:

In July of 2023, Geoff was named CEO of Noom, Inc., a leading digital health platform combining personalized psychology with modern medicine.
Before that, Geoff executed numerous acquisitions while growing The Meet Group, and ultimately sold it in 2020 for approximately $500 million to ProSiebenSat.1 Media.
6,683,858, and on January 19, 2023, the Examiner issued an Ex Parte Reexamination Certificate, ending the reexamination and confirming the patentability of claims 1-10 of U.S. Patent No.
On June 29, 2023, the Court held a pretrial conference with the parties and denied Cisco’s motion for summary judgement.

EQS-News: EcoGraf Limited: Australian Patent Application

Retrieved on:

Tuesday, August 22, 2023

EcoGraf Limited (EcoGraf or the Company) (ASX: EGR; FSE: FMK; OTCQX: ECGFF) has been made aware of an ASX announcement by Renascor Resources Limited (ASX: RNU) (Renascor) dated 10 August 2023 in which Renascor states “As reported in April 2022, Renascor lodged an opposition to a pending patent application relating to the purification of graphite.

Key Points:

EcoGraf Limited (EcoGraf or the Company) (ASX: EGR; FSE: FMK; OTCQX: ECGFF) has been made aware of an ASX announcement by Renascor Resources Limited (ASX: RNU) (Renascor) dated 10 August 2023 in which Renascor states “As reported in April 2022, Renascor lodged an opposition to a pending patent application relating to the purification of graphite.
Renascor considers the pending patent application to be overly broad and relating to processing procedures that are not sufficiently novel or inventive to merit patent protection.”
EcoGraf understands that the patent application referred to by Renascor in that announcement is the same patent application made by EcoGraf and referred to in its ASX announcement dated 8 November 2021.
As reported by EcoGraf in the announcement to ASX on 8 November 2021:
The International Preliminary Examining Authority of the Patent Co-operation Treaty has deemed the EcoGraf™ purification process as novel and inventive.
Accordingly, the Company strongly disagrees with the statement by Renascor and notes that EcoGraf has also received notice from the US Patent and Trademark Office that its patent application “Method of Producing Purified Graphite” has been granted on 18 July 2023 as United States Patent 11,702342.

Paltalk, Inc. Reports 12% Revenue Growth to $3.0 Million in Second Quarter 2023

Retrieved on:

Tuesday, August 8, 2023

JERICHO, NY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Paltalk, Inc. (“Paltalk,” the “Company,” “we,” “our” or “us”) (Nasdaq: PALT), a communications software innovator that powers multimedia social applications, today announced financial and operational results for the second quarter ended June 30, 2023.

Key Points:

All of our attention and efforts to optimize our platforms and streamline our costs have paid off and improved our foundation.
Our infrastructure is capable of supporting additional business, so if we continue to expand revenue, we are confident that it would result in increased profitability.
Financial Results for Three Months Ended June 30, 2023
Revenue for the three months ended June 30, 2023 increased by 11.8% to $3.0 million, compared to $2.6 million for the three months ended June 30, 2022.
Financial Results for Six Months Ended June 30, 2023
Revenue for the six months ended June 30, 2023 decreased by 0.9% to $5.5 million, compared to $5.6 million for the six months ended June 30, 2022.

Lovevery Adds a Fifth Year to Its Early Learning Program with The Play Kits for Four-Year-Olds

Retrieved on:

Wednesday, May 31, 2023

Child, Plan, Parent, Discover, Examiner, Experiential learning, Planner, Executive functions, Function (mathematics), Management, Toy, Lovevery

BOISE, Idaho, May 31, 2023 /PRNewswire/ -- Lovevery, the global early childhood brand, today announced the expansion of its subscription early learning program with Play Kits for four-year-olds. Lovevery has applied their innovative approach to a fifth year of life, giving parents a holistic support system for their child as they build skills that lay a foundation of executive function.

Key Points:

BOISE, Idaho, May 31, 2023 /PRNewswire/ -- Lovevery, the global early childhood brand, today announced the expansion of its subscription early learning program with Play Kits for four-year-olds.
Lovevery has applied their innovative approach to a fifth year of life, giving parents a holistic support system for their child as they build skills that lay a foundation of executive function.
"The resource that we've created for four-year-olds and their parents is unmatched as the essential skill-building program for this crucial year of early learning.
Adding a fifth year to our Play Kits program is an important step towards reaching the fullest potential of our core mission."

Paltalk, Inc. Reports First Quarter 2023 Financial Results

Retrieved on:

Tuesday, May 9, 2023

JERICHO, NY , May 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Paltalk, Inc. (“Paltalk,” the “Company,” “we,” “our” or “us”) (Nasdaq: PALT), a communications software innovator that powers multimedia social applications, today announced financial and operational results for the first quarter ended March 31, 2023.

Key Points:

$13.9 Million in Cash and Cash Equivalents at March 31, 2023
JERICHO, NY , May 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Paltalk, Inc. (“Paltalk,” the “Company,” “we,” “our” or “us”) (Nasdaq: PALT), a communications software innovator that powers multimedia social applications, today announced financial and operational results for the first quarter ended March 31, 2023.
On September 7, 2022, the United States Patent Office issued a reexamination of U.S. Patent No.
6,683,858, and on January 19, 2023, the Examiner issued an Ex Parte Reexamination Certificate, ending the reexamination and confirming the patentability of claims 1-10 of U.S. Patent No.
A trial is scheduled for early third quarter of 2023.